Apheresis is the process of separating the blood and removing or manipulating a cellular or plasma component for therapeutic benefit. Such procedures may be indicated in the critical care setting as primary or adjunctive therapy for certain hematologic, neurologic, renal, and autoimmune/rheumatologic disorders. In part I of this series, the technical aspects of apheresis were described and the physiologic rationale and clinical considerations were discussed. This review highlights the pathophysiologic basis, specific clinical indications, and treatment parameters for disorders that more commonly require management in the intensive care unit. The choice of plasma or cellular apheresis in these cases is guided by wellaccepted, evidence-based clinical treatment guidelines. For some disorders, such as liver failure, severe sepsis, and multiple-organ dysfunction syndrome, apheresis treatment approaches remain experimental. Ongoing studies are investigating the potential utility of conventional plasma exchange, ex vivo plasma manipulation, and newer technologies for these and other disorders in severely ill patients.
McLeod BC. Introduction to the third special issue: clinical applications of therapeutic apheresis. J Clin Apheresis. 2000;15:1-5.
2.
Smith JW, Weinstein R, for the AHCKL. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion. 2003;43:820-822.
3.
McLeod BC, Sniecinski I, Ciavarella D, et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999;39:282-288.
4.
Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 1999;131:453-462.
5.
Nabhan C, Kwaan HC. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am. 2003;17:177-199.
6.
Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpurahemolytic uremic syndrome during pregnancy. J Clin Apheresis. 2001;16:202-209.
9.
Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.
10.
Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127:834-839.
11.
Raife T, Atkinson B, Montgomery R, et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004;44:146-150.
12.
Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med. 2002;126:1430-1433.
13.
Moore JC, Hayward CP, Warkentin TE, et al. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001;98:1842-1846.
14.
Grima KM. Therapeutic apheresis in hematological and oncological diseases. J Clin Apheresis. 2000;15:28-52.
15.
Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-397.
16.
Lara PN Jr, Coe TL, Zhou H, et al. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med. 1999;107:573-579.
17.
George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223-1229.
18.
Knobl P, Rintelen C, Kornek G, et al. Plasma exchange for treatment of thrombotic thrombocytopenic purpura in critically ill patients. Intensive Care Med. 1997;23:44-50.
19.
Novitzky N, Jacobs P, Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange?Br J Haematol. 1994;87:317-320.
20.
Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore).2003;82:27-38.
21.
Gordjani N, Sutor AH, Zimmerhackl LB, et al. Hemolytic uremic syndromes in childhood. Semin Thromb Hemost. 1997;23:281-293.
22.
Winters JL, Pineda AA, McLeod BC, et al. Therapeutic apheresis in renal and metabolic diseases. J Clin Apheresis. 2000;15:53-73.
23.
Teruya J, Styler M, Verde S, et al. Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation. J Clin Apheresis. 2001;16:169-174.
24.
Allford SL, Bird JM, Marks DI. Thrombotic thrombocytopenic purpura following stem cell transplantation. Leuk Lymphoma. 2002;43:1921-1926.
25.
Zheng X, Pallera AM, Goodnough LT, et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105-108.
26.
Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol. 1996;94:383-386.
27.
Barz D, Budde U, Hellstern P. Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thromb Res. 2002;107(suppl 1):S23-S27.
28.
Ellis J, Theodossiou C, Schwarzenberger P. Treatment of thrombotic thrombocytopenic purpura with the cryosupernatant fraction of plasma: a case report and review of the literature. Am J Med Sci. 1999;318:190-193.
29.
Rizvi MA, Vesely SK, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpurahemolytic-uremic syndrome. Transfusion. 2000;40:896-901.
30.
McMinn JR Jr, Thomas IA, Terrell DR, et al. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion.2003;43:415-416.
Kieseier BC, Hartung HP. Therapeutic strategies in the Guillain-Barre syndrome. Semin Neurol. 2003;23:159-168.
33.
Sharshar T, Chevret S, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barre syndrome. Crit Care Med. 2003;31:278-283.
34.
Wijdicks EF, Henderson RD, McClelland RL. Emergency intubation for respiratory failure in Guillain-Barre syndrome. Arch Neurol. 2003;60:947-948.
35.
Green DM, Ropper AH. Mild Guillain-Barre syndrome. Arch Neurol. 2001;58:1098-1101.
36.
Vriesendorp FJ, Mishu B, Blaser MJ, et al. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barre syndrome and controls: correlation and prognosis. Ann Neurol. 1993;34:130-135.
37.
Visser LH, Schmitz PI, Meulstee J, et al. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group. Neurology. 1999;53:598-604.
38.
Yuki N, Ang CW, Koga M, et al. Clinical features and response to treatment in Guillain-Barre syndrome associated with antibodies to GM1b ganglioside. Ann Neurol. 2000;47:314-321.
39.
Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol. 1987;22:753-761.
40.
Vriesendorp FJ, Mayer RF, Koski CL. Kinetics of antiperipheral nerve myelin antibody in patients with Guillain-Barre syndrome treated and not treated with plasmapheresis. Arch Neurol. 1991;48:858-861.
41.
van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123-1129.
42.
Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol. 1997;41:298-306.
43.
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225-230.
44.
Weinstein R.Therapeutic apheresis in neurological disorders. J Clin Apheresis. 2000;15:74-128.
45.
Raphael JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 2001;71:235-238.
46.
Inoue N, Kunishige M, Yoshida S, et al. Dissociation between titer of anti-ganglioside antibody and severity of symptoms in a case of Guillain-Barre syndrome with treatmen trelated fluctuation. J Neurol Sci. 2003;210:105-108.
47.
McLeod BC. Therapeutic plasma exchange in neurologic disorders. In McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed.Bethesda, Md: AABB; 2003:321-344.
48.
Winters JL, Pineda AA. New directions in plasma exchange. Curr Opin Hematol. 2003;10:424-428.
49.
Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barre syndrome. Neurology. 1998;51:875-877.
50.
Esperou H, Jars-Guincestre MC, Bolgert F, et al. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barre syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Intensive Care Med. 2000;26:1094-1100.
51.
Bouget J, Chevret S, Chastang C, et al. Plasma exchange morbidity in Guillain-Barre syndrome: results from the French prospective, randomized, multicenter study. The French Cooperative Group. Crit Care Med. 1993;21:651-658.
52.
Chen WH, Yeh JH, Chiu HC. Experience of double filtration plasmapheresis in the treatment of Guillain-Barre syndrome. J Clin Apheresis. 1999;14:126-129.
53.
Lyu RK, Chen WH, Hsieh ST. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barre syndrome. Ther Apher. 2002;6:163-166.
54.
Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39:1-18.
Vernant JP, Brun B, Mannoni P, et al. Respiratory distress of hyperleukocytic granulocytic leukemias. Cancer. 1979;44:264-268.
57.
Lester TJ, Johnson JW, Cuttner J. Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis. Am J Med. 1985;79:43-48.
58.
Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol. 1985;3:1590-1595.
59.
Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987;5:1364-1372.
60.
Ventura GJ, Hester JP, Smith TL, et al. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol. 1988;27:34-37.
Szyper-Kravitz M, Strahilevitz J, Oren V, et al. Pulmonary leukostasis: role of perfusion lung scan in diagnosis and follow up. Am J Hematol. 2001;67:136-138.
63.
McCormick J III, Henderson SO. Leukemic hyperleukocytosis induced unstable angina and congestive heart failure. Am J Emerg Med. 1999;17:217-219.
64.
da Costa CM, de Camargo B, Gutierrez y Lamelas R, et al. Cardiac tamponade complicating hyperleukocytosis in a child with leukemia. Med Pediatr Oncol. 1999;33:120-124.
65.
Cohen Y, Amir G, Da'as N, et al. Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis. Am J Hematol. 2002;71:47-49.
66.
Maurer HS, Steinherz PG, Gaynon PS, et al. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol. 1988;6:1425-1432.
67.
Karp DD, Beck JR, Cornell CJ Jr.Chronic granulocyte leukemia with respiratory distress. Efficacy of emergency leukapheresis. Arch Intern Med. 1981;141:1353-1354.
68.
Resende LS, Coradazzi AL, Rocha-Junior C, et al. Sudden bilateral deafness from hyperleukocytosis in chronic myeloid leukemia. Acta Haematol. 2000;104:46-49.
69.
Nowacki P, Zdziarska B, Fryze C, et al. Co-existence of thrombocytopenia and hyperleukocytosis (“critical period”) as a risk factor of haemorrhage into the central nervous system in patients with acute leukaemias. Haematologia (Budap).2002;31:347-355.
70.
Stemmler J, Wittmann GW, Hacker U, et al. Leukapheresis in chronic myelomonocytic leukemia with leukostasis syndrome: elevated serum lactate levels as an early sign of microcirculation failure. Leuk Lymphoma. 2002;43:1427-1430.
71.
Baer MR, Stein RS, Dessypris EN. Chronic lymphocytic leukemia with hyperleukocytosis. The hyperviscosity syndrome. Cancer. 1985;56:2865-2869.
72.
Cukierman T, Gatt ME, Libster D, et al. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma. 2002;43:1865-1868.
73.
Thomas X, Anglaret B, Bailly M, et al. Differential adhesiveness between blood and marrow leukemic cells having similar pattern of VLA adhesion molecule expression. Leuk Res. 1998;22:953-960.
74.
Stucki A, Rivier AS, Gikic M, et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121-2129.
75.
Azoulay E, Fieux F, Moreau D, et al. Acute monocytic leukemia presenting as acute respiratory failure. Am J Respir Crit Care Med. 2003;167:1329-1333.
76.
Roberts TF, Sprague K, Schenkein D, et al. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Blood. 2000;96:4000-4001.
77.
Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003;17:1454-1463.
78.
Einzig AI, Dutcher JP, Wiernik PH. Life-threatening hyperleukocytosis and pulmonary compromise after priming with recombinant human granulocyte-macrophage colonystimulating factor in a patient with acute myelomonocytic leukemia. J Clin Oncol. 1995;13:304-305.
79.
Wurthner JU, Kohler G, Behringer D, et al. Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: a clinicopathologic report of four cases. Cancer. 1999;85:368-374.
80.
Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute leukemia. Ther Apher. 2002;6:15-23.
81.
Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. Semin Thromb Hemost. 2003;29:535-542.
82.
Flasshove M, Schuette J, Sauerwein W, et al. Pulmonary and cerebral irradiation for hyperleukocytosis in acute myelomonocytic leukemia. Leukemia. 1994;8:1792-1792.
83.
Nelson SC, Bruggers CS, Kurtzberg J, et al. Management of leukemic hyperleukocytosis with hydration, urinary alkalinization, and allopurinol. Are cranial irradiation and invasive cytoreduction necessary?Am J Pediatr Hematol Oncol. 1993;15:351-355.
84.
Hug V, Keating M, McCredie K, et al. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer. 1983;52:773-779.
85.
Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival. Leuk Lymphoma. 2001;42:67-73.
86.
Thiebaut A, Thomas X, Belhabri A, et al. Impact of preinduction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000;79:501-506.
87.
Estey E.Reducing mortality associated with immediate treatment complications of adult leukemias. Semin Hematol. 2001;38:32-37.
88.
Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997;89:1787-1792.
89.
Stuart MJ, Setty BN. Acute chest syndrome of sickle cell disease: new light on an old problem. Curr Opin Hematol. 2001;8:111-122.
90.
Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762-769.
91.
Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol. 2002;9:101-106.
92.
Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood. 1999;94:1555-1560.
Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855-1865.
95.
Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood. 1994;83:3107-3112.
96.
Pepkowitz S.Red cell exchange and other therapeutic alterations of red cell mass. In McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed.Bethesda, Md: AABB; 2003:411-436.
97.
Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81:1109-1123.
98.
Davies SC, Roberts-Harewood M. Blood transfusion in sickle cell disease. Blood Rev. 1997;11:57-71.
99.
Reed W, Vichinsky EP. Transfusion therapy: a coming of age treatment for patients with sickle cell disease. J Pediatr Hematol Oncol. 2001;23:197-202.
100.
Uchida K, Rackoff WR, Ohene-Frempong K, et al. Effect of erythrocytapheresis on arterial oxygen saturation and hemoglobin oxygen affinity in patients with sickle cell disease. Am J Hematol. 1998;59:5-8.
101.
Liem RI, O'Gorman MR, Brown DL. Effect of red cell exchange transfusion on plasma levels of inflammatory mediators in sickle cell patients with acute chest syndrome. Am J Hematol. 2004;76:19-25.
102.
Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion. 1987;27:228-233.
103.
Lawson SE, Oakley S, Smith NA, et al. Red cell exchange in sickle cell disease. Clin Lab Haematol. 1999;21:99-102.
104.
Danielson CF. The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. Ther Apher. 2002;6:24-31.
105.
Lombardo T, Rosso R, La Ferla A, et al. Acute chest syndrome: the role of erythro-exchange in patients with sickle cell disease in Sicily. Transfus Apheresis Sci. 2003;29:39-44.
106.
Vichinsky E.Consensus document for transfusion-related iron overload. Semin Hematol. 2001;38:2-4.
107.
Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol. 2001;38:14-22.
108.
Hilliard LM, Williams BF, Lounsbury AE, et al. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol. 1998;59:28-35.
109.
Talacki CA, Ballas SK. Modified method of exchange transfusion in sickle cell disease. J Clin Apheresis. 1990;5:183-187.
110.
Firth PG, Tsuruta Y, Kamath Y, et al. Transfusion-related acute lung injury or acute chest syndrome of sickle cell disease? A case report. Can J Anaesth. 2003;50:895-899.
111.
Wratney AT, Gentile MA, Hamel DS, et al. Successful treatment of acute chest syndrome with high-frequency oscillatory ventilation in pediatric patients. Respir Care. 2004;49:263-269.
112.
Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 1998;92:3082-3089.
113.
Knight-Madden JA, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev. 2003:CD003733.
114.
Vichinsky E.New therapies in sickle cell disease. Lancet. 2002;360:629-631.
115.
Morris CR, Vichinsky EP, van Warmerdam J, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol. 2003;25:629-634.
116.
Madore F.Plasmapheresis. Technical aspects and indications. Crit Care Clin. 2002;18:375-392.
Szczepiorkowski ZM. TPE in renal, rheumatic, and miscellaneous disorders. In McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed.Bethesda, Md: AABB; 2003:375-409.
119.
Kaplan AA. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher. 2001;5:171-175.
120.
Koo AP. Therapeutic apheresis in autoimmune and rheumatic diseases. J Clin Apheresis. 2000;15:18-27.
121.
Abraham KA, Brown C, Conlon PJ, et al. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J Clin Apheresis. 2003;18:103-110.
122.
Moist L, Nesrallah G, Kortas C, et al. Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol. 1999;19:45-50.
123.
Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apher. 2002;6:45-52.
124.
Hirasawa H, Sugai T, Oda S, et al. Efficacy and limitation of apheresis therapy in critical care. Ther Apher. 1997;1:228-232.
125.
Fabrizi F, Colucci P, Ponticelli C, et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol. 2002;22:309-318.
126.
Dominguez JH, Sha E. Apheresis in cryoglobulinemia complicating hepatitis C and in other renal diseases. Ther Apher. 2002;6:69-76.
127.
Della Rossa A, Tavoni A, Bombardieri S. Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations. Semin Thromb Hemost. 2003;29:473-477.
128.
Levy J, Degani N. Correcting immune imbalance: the use of Prosorba column treatment for immune disorders. Ther Apher Dial. 2003;7:197-205.
129.
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
130.
Flamholz R, Tran T, Grad GI, et al. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apheresis. 1999;14:171-176.
131.
Westney GE, Harris EN. Catastrophic antiphospholipid syndrome in the intensive care unit. Crit Care Clin. 2002;18:805-817.
132.
Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-534.
133.
Koschmieder S, Miesbach W, Fauth F, et al. Combined plasmapheresis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report. Blood Coagul Fibrinolysis. 2003;14:395-399.
134.
von Baeyer H.Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidencebased medicine and clinical experience. Ther Apher Dial. 2003;7:127-140.
135.
Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore).2001;80:355-377.
136.
Greist A.The role of blood component removal in essential and reactive thrombocytosis. Ther Apher. 2002;6:36-44.
137.
Valbonesi M, Bruni R. Clinical application of therapeutic erythrocytapheresis (TEA). Transfus Sci. 2000;22:183-194.
138.
Drew MJ. Therapeutic plasma exchange in hematologic diseases and dysproteinemias. In McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed.Bethesda, Md: AABB; 2003:345-373.
139.
Kumar R, Ghali A, Ekaldious AW, et al. Post-transfusion purpura: case report. Ann Hematol. 2001;80:488-491.
140.
Ogata H, Sakai S, Koiwa F, et al. Plasma exchange for acquired hemophilia: a case report. Ther Apher. 1999;3:320-322.
141.
Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol. 2001;5:389-404.
142.
Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol. 2001;112:91-97.
143.
Freedman J, Rand ML, Russell O, et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion. 2003;43:1508-1513.
144.
Miller KD, Greenberg AE, Campbell CC. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med. 1989;321:65-70.
145.
White NJ. The treatment of malaria. N Engl J Med. 1996;335:800-806.
146.
Macallan DC, Pocock M, Bishop E, et al. Automated erythrocytapheresis in the treatment of severe falciparum malaria. J Infect. 1999;39:233-236.
147.
Tejura B, Sass DA, Fischer RA, et al. Transfusion-associated falciparum malaria successfully treated with red blood cell exchange transfusion. Am J Med Sci. 2000;320:337-341.
148.
Zhang Y, Telleria L, Vinetz JM, et al. Erythrocytapheresis for Plasmodium falciparum infection complicated by cerebral malaria and hyperparasitemia. J Clin Apheresis. 2001;16:15-18.
149.
Bruneel F, Hocqueloux L, Alberti C, et al. The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med. 2003;167:684-689.
150.
Evenson DA, Perry E, Kloster B, et al. Therapeutic apheresis for babesiosis. J Clin Apheresis. 1998;13:32-36.
151.
Pantanowitz L, Telford SR III, Cannon ME. The impact of babesiosis on transfusion medicine. Transfus Med Rev. 2002;16:131-143.
Hughes RA. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. Rev Neurol (Paris).2002;158:S32-S36.
157.
Batocchi AP, Evoli A, Di Schino C, et al. Therapeutic apheresis in myasthenia gravis. Ther Apher. 2000;4:275-279.
158.
Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002:CD002275.
159.
Ronager J, Ravnborg M, Hermansen I, et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25:967-973.
160.
Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543-1554.
161.
Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2003:CD003279.
162.
Motomura M, Hamasaki S, Nakane S, et al. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher. 2000;4:287-290.
163.
Das A, Hochberg FH, McNelis S. A review of the therapy of paraneoplastic neurologic syndromes. J Neurooncol. 1999;41:181-194.
164.
Toyka KV, Gold R. The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents. Neurology. 2003;60:S2-S7.
165.
Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878-886.
166.
Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58:143-146.
167.
Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-178.
168.
Golden PJ, Weinstein R. Treatment of high-risk, refractory acquired methemoglobinemia with automated red blood cell exchange. J Clin Apheresis. 1998;13:28-31.
169.
Reichheld JH, Katz E, Banner BF, et al. The value of intravenous heme-albumin and plasmapheresis in reducing postoperative complications of orthotopic liver transplantation for erythropoietic protoporphyria. Transplantation. 1999;67:922-928.
170.
Azuma E, Nishihara H, Hanada M, et al. Recurrent cold hemagglutinin disease following allogeneic bone marrow transplantation successfully treated with plasmapheresis, corticosteroid and cyclophosphamide. Bone Marrow Transplant. 1996;18:243-246.
171.
Roy-Burman A, Glader BE. Resolution of severe Donath-Landsteiner autoimmune hemolytic anemia temporally associated with institution of plasmapheresis. Crit Care Med. 2002;30:931-934.
172.
Matsumoto Y, Naniwa D, Banno S, et al. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher. 1998;2:300-304.
173.
Coman T, Dalloz MA, Coolen N, et al. Plasmapheresis for the treatment of acute pancreatitis induced by hemophagocytic syndrome related to hypertriglyceridemia. J Clin Apheresis. 2003;18:129-131.
174.
Tiftik N, Kiykim A, Altintas E, et al. Therapeutic plasma exchange for multidrug intoxication: a case report. J Clin Apheresis. 2003;18:132-133.
175.
Nenov VD, Marinov P, Sabeva J, et al. Current applications of plasmapheresis in clinical toxicology. Nephrol Dial Transplant. 2003;18(suppl 5):v56-v58.
176.
Yamada H, Takamori K, Yaguchi H, et al. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher. 1998;2:153-156.
177.
Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.
178.
Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002;6:225-228.
179.
Furubacke A, Berlin G, Anderson C, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?Intensive Care Med. 1999;25:1307-1310.
180.
Frieling JT, van Deuren M, Wijdenes J, et al. Interleukin-6 and its soluble receptor during acute meningococcal infections: effect of plasma or whole blood exchange. Crit Care Med. 1996;24:1801-1805.
181.
van Deuren M, Frieling JT, van der Ven-Jongekrijg J, et al. Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin Infect Dis. 1998;26:918-923.
182.
Ataman K, Jehmlich M, Kock S, et al. Short-term cardiovascular effects of plasmapheresis in norepinephrinerefractory septic shock. Intensive Care Med. 2002;28:1164-1167.
183.
Reeves JH, Butt WW, Shann F, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med. 1999;27:2096-2104.
184.
Yang KS, Kenpe K, Yamaji K, et al. Plasma adsorption in critical care. Ther Apher. 2002;6:184-188.
185.
Stegmayr BG. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Ther Apher. 2001;5:123-127.
186.
Tsushima K, Kubo K, Koizumi T, et al. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J Clin Apheresis. 2002;17:97-102.
187.
Matsuda K, Hirasawa H, Oda S, et al. Current topics on cytokine removal technologies. Ther Apher. 2001;5:306-314.
188.
Vamvakas EC, Pineda AA. Selective extraction of plasma constituents. In McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed.Bethesda, Md: AABB; 2003:437-476.
189.
Hart GK. Plasmapheresis in intensive care. Part 2 of 2: indications for plasmapheresis and plasma exchange in the intensive care unit. Intensive Care World. 1990;7:80-84.
190.
Schmidt J, Mann S, Mohr VD, et al. Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis. Intensive Care Med. 2000;26:532-537.
191.
Stegmayr BG, Banga R, Berggren L, et al. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med. 2003;31:1730-1736.
192.
Busund R, Koukline V, Utrobin U, et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002;28:1434-1439.
193.
Carcillo JA, Kellum JA. Is there a role for plasmapheresis/ plasma exchange therapy in septic shock, MODS, and thrombocytopenia-associated multiple organ failure? We still do not know—but perhaps we are closer. Intensive Care Med. 2002;28:1373-1375.
